- Investing Ideas
- U.K. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
U.K. Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
3
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
3 companies
AstraZeneca
Market Cap: UK£183.7b
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AZN
UK£118.44
7D
0.9%
1Y
6.8%
Diaceutics
Market Cap: UK£126.5m
A diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.
DXRX
UK£1.49
7D
3.1%
1Y
8.4%
hVIVO
Market Cap: UK£47.4m
Operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America.
HVO
UK£0.069
7D
0%
1Y
-36.7%